Oppenheimer Asset Management Inc. lifted its position in Bristol-Myers Squibb Company (NYSE:BMY) by 185.9% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 232,376 shares of the biopharmaceutical company’s stock after acquiring an additional 151,105 shares during the period. Oppenheimer Asset Management Inc.’s holdings in Bristol-Myers Squibb were worth $12,948,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other large investors have also recently modified their holdings of the company. Tradewinds Capital Management LLC boosted its stake in shares of Bristol-Myers Squibb by 34.6% in the second quarter. Tradewinds Capital Management LLC now owns 1,945 shares of the biopharmaceutical company’s stock worth $108,000 after acquiring an additional 500 shares during the last quarter. Blue Chip Partners Inc. boosted its stake in shares of Bristol-Myers Squibb by 0.8% in the first quarter. Blue Chip Partners Inc. now owns 2,141 shares of the biopharmaceutical company’s stock worth $116,000 after acquiring an additional 17 shares during the last quarter. American National Bank boosted its stake in shares of Bristol-Myers Squibb by 11.7% in the second quarter. American National Bank now owns 2,144 shares of the biopharmaceutical company’s stock worth $119,000 after acquiring an additional 225 shares during the last quarter. BDO Wealth Advisors LLC acquired a new stake in shares of Bristol-Myers Squibb in the second quarter worth approximately $123,000. Finally, Proficio Capital Partners LLC boosted its stake in shares of Bristol-Myers Squibb by 29.6% in the first quarter. Proficio Capital Partners LLC now owns 2,204 shares of the biopharmaceutical company’s stock worth $119,000 after acquiring an additional 504 shares during the last quarter. 68.97% of the stock is currently owned by hedge funds and other institutional investors.
In related news, SVP Joseph C. Caldarella sold 9,340 shares of the business’s stock in a transaction on Wednesday, September 6th. The stock was sold at an average price of $60.00, for a total value of $560,400.00. Following the sale, the senior vice president now owns 46,297 shares in the company, valued at approximately $2,777,820. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 0.23% of the stock is currently owned by insiders.
A number of analysts have recently issued reports on BMY shares. Hilliard Lyons lowered Bristol-Myers Squibb from a “long-term buy” rating to a “neutral” rating and set a $65.00 price target on the stock. in a research note on Tuesday, September 12th. Goldman Sachs Group, Inc. (The) reaffirmed a “buy” rating and issued a $65.00 price target (up from $62.00) on shares of Bristol-Myers Squibb in a research note on Thursday, September 7th. SunTrust Banks, Inc. upgraded Bristol-Myers Squibb from a “hold” rating to a “buy” rating in a research report on Monday, October 30th. Zacks Investment Research upgraded Bristol-Myers Squibb from a “hold” rating to a “buy” rating and set a $68.00 price objective on the stock in a research report on Wednesday, November 1st. Finally, Barclays PLC lifted their price objective on Bristol-Myers Squibb from $58.00 to $65.00 and gave the stock an “equal weight” rating in a research report on Friday, October 13th. One research analyst has rated the stock with a sell rating, ten have assigned a hold rating and eleven have issued a buy rating to the company. The stock has an average rating of “Hold” and a consensus target price of $64.93.
Shares of Bristol-Myers Squibb Company (NYSE BMY) opened at $61.32 on Monday. The company has a quick ratio of 1.46, a current ratio of 1.59 and a debt-to-equity ratio of 0.47. The stock has a market capitalization of $100,360.00, a price-to-earnings ratio of 20.72, a P/E/G ratio of 2.42 and a beta of 1.18. Bristol-Myers Squibb Company has a 1-year low of $46.01 and a 1-year high of $66.10.
Bristol-Myers Squibb (NYSE:BMY) last posted its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.77 by ($0.02). The firm had revenue of $5.25 billion during the quarter, compared to analysts’ expectations of $5.20 billion. Bristol-Myers Squibb had a net margin of 20.56% and a return on equity of 32.41%. Bristol-Myers Squibb’s quarterly revenue was up 6.7% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.77 EPS. research analysts forecast that Bristol-Myers Squibb Company will post 2.99 earnings per share for the current fiscal year.
The company also recently disclosed a quarterly dividend, which was paid on Wednesday, November 1st. Investors of record on Friday, October 6th were issued a $0.39 dividend. The ex-dividend date of this dividend was Thursday, October 5th. This represents a $1.56 annualized dividend and a dividend yield of 2.54%. Bristol-Myers Squibb’s dividend payout ratio is presently 61.42%.
Bristol-Myers Squibb Company Profile
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Receive News & Ratings for Bristol-Myers Squibb Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Company and related companies with MarketBeat.com's FREE daily email newsletter.